It’s interesting to see that big pharmaceutical companies begin to invest in web 2.0 communication.
Indeed, most of them have launched a YouTube channel targeting specific diseases and then, a tiny targeted group of patient.
Sanofi-Aventis launched its inaugural YouTube channel on February 4. Titled GoInsulin, the channel which is unbranded features provides personal stories of patients with diabetes and links to GoInsulin.com, a companion website.
Another good example is the AstraZeneca channel also launched in February. In this case, it’s a branded YouTube channel for its asthma drug Symbicort. It tells stories of patients affected by asthma. The company also launched a microsite, myasthmastory.com where patients can tell their personal experience of the disease.
We strongly belief that expanding social media platforms will play an increasing role with patients, and can be used to effectively deliver information on the risks and benefits of treatments.
The two pharmaceutical companies join Johnson & Johnson, Abbott Labs, and GlaxoSmithKline in the YouTube space.
http://www.youtube.com/user/goinsulin
http://www.youtube.com/myasthmastory
